BL(SZ:002592)2019-04-24 16:00Financial Performance - The company's revenue for Q1 2019 was CNY 201,859,236.50, representing a 14.13% increase compared to CNY 176,861,933.74 in the same period last year[7] - The net profit attributable to shareholders was a loss of CNY 6,929,832.04, a decrease of 207.81% from a profit of CNY 6,427,743.18 in the previous year[7] - The company reported a basic earnings per share of -CNY 0.03, down 250.00% from CNY 0.02 in the same period last year[7] - The weighted average return on equity was -0.37%, a decline of 0.67% compared to 0.30% in the previous year[7] - The total operating revenue for the first quarter of 2019 was CNY 201,859,236.50, an increase of 14.1% compared to CNY 176,861,933.74 in the same period last year[54] - The total operating costs amounted to CNY 208,490,089.48, up from CNY 175,494,596.46, reflecting a year-over-year increase of 18.8%[54] - The net profit attributable to the parent company was CNY 356,039,102.14, slightly down from CNY 357,839,894.32 in the previous quarter[53] - The total comprehensive income for Q1 2019 was -¥6,936,687.59, compared to ¥6,206,268.59 in Q1 2018[57] - The total profit for Q1 2019 was -¥5,915,303.33, compared to a profit of ¥8,655,246.35 in the same period last year[56] Cash Flow - The net cash flow from operating activities was CNY 19,698,912.78, a significant improvement from a negative cash flow of CNY 48,080,732.27 in the same period last year, marking a 140.97% change[7] - Net cash flow from operating activities improved by 140.97% to ¥19,698,912.78, driven by a 54.43% increase in cash received from sales[18] - Operating cash inflow totaled CNY 133,878,330.66, an increase from CNY 76,298,884.80 in the previous period[68] - Net cash flow from operating activities was CNY 42,720,823.61, compared to a negative CNY 40,103,839.37 in the previous period[68] - Cash inflow from financing activities was CNY 14,999,647.13, compared to CNY 70,000,000.00 in the previous period[69] - Net cash flow from financing activities was negative CNY 24,058,492.32, compared to negative CNY 16,465,512.08 in the previous period[69] Assets and Liabilities - The total assets at the end of the reporting period were CNY 2,370,940,909.55, a decrease of 1.09% from CNY 2,397,070,604.58 at the end of the previous year[7] - The company's current assets totaled 869,791,394.82 CNY, slightly up from 860,642,752.41 CNY at the end of 2018[45] - The company's non-current assets decreased from 1,536,427,852.17 CNY to 1,501,149,514.73 CNY during the same period[46] - The total liabilities were CNY 588,653,410.32, compared to CNY 588,203,541.47 in the previous quarter, indicating a marginal increase[52] - The company's short-term borrowings decreased from 180 million CNY to 160 million CNY[46] - The long-term borrowings decreased significantly to CNY 15,017,976.83 from CNY 23,588,285.52, a reduction of 36.5%[52] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 14,954[10] - The largest shareholder, Yang Jingzhong, holds 33.45% of the shares, with 94,766,049 shares pledged[10] - The company is undergoing a share buyback plan with a budget of between RMB 100 million and RMB 300 million, with a maximum price of RMB 16.35 per share[33] - The company repurchased a total of 16,826,900 shares, accounting for 5.94% of the total share capital, with an average transaction price of 12.58 CNY per share, totaling 211,609,144 CNY[34] Investments and Acquisitions - The company plans to implement a fourth employee stock ownership plan, transferring 16,826,900 shares at a price of ¥21.42 per share, totaling ¥360,432,198[20] - The company is in the process of transferring its entire investment in Gaia Bailing, valued at ¥10,391.67 million, to Horgos Gaia Network Technology Co., Ltd.[22] - The acquisition of a 51% stake in Beijing Hongrun Tianyuan Gene Biotechnology Co., Ltd. has been approved by the board and is pending shareholder approval[24] - The company plans to acquire 51% of Beijing Hongrun Tianyuan Gene Biotechnology Co., Ltd. for a cash payment of RMB 907.75 million[25] - The company intends to use RMB 489.31 million from the balance of fundraising accounts, including interest, for the acquisition of the 51% stake in Hongrun Tianyuan[26] - The company will increase its investment in Kewah Biotechnology Co., Ltd. by RMB 66 million, raising its registered capital from RMB 30 million to RMB 38.46 million, with the company holding 22% of the increased capital[29] - The company has already paid RMB 20 million of the investment to Kewah Biotechnology Co., Ltd.[32] Expenses - Management expenses increased by 51.79% to ¥13,207,862.74, primarily due to higher salary costs and intermediary fees[16] - Financial expenses decreased by 69.47% to -¥1,292,131.43, attributed to an increase in short-term and long-term borrowings[16] - Asset impairment losses surged by 1271.23% to ¥1,588,954.44, mainly due to increased bad debt provisions[16] - Investment income dropped by 121.61% to -¥1,263,009.58, reflecting decreased profits from associated companies[16] - Research and development expenses for Q1 2019 were ¥4,785,256.82, down from ¥6,319,092.69 in Q1 2018, reflecting a reduction in R&D investment[59] - The company reported an asset impairment loss of ¥9,697,995.56 in Q1 2019, compared to ¥8,279,258.23 in the previous year[59]